Core Viewpoint - Agape ATP Corp. (NASDAQ:ATPC) experienced a significant after-hours stock price increase of 64.86% to $0.12, following a regular session close at $0.07, which was a 6.06% increase [1] Group 1: Company Overview - Agape ATP Corporation is an investment holding company based in Malaysia, focusing on health and wellness products and sustainable energy solutions [3] - The company has a market capitalization of $3.30 million, with shares trading between a 52-week high of $2.57 and a 52-week low of $0.05 [3] Group 2: Stock Performance and Volatility - Over the past 12 months, the company's stock has declined by 94.81%, indicating significant challenges and a deeply negative long-term trend despite short-term opportunities [4] - The stock is currently trading at 0.79% of its 52-week range, suggesting weak market sentiment and the need for monitoring potential reversals or further declines [4] Group 3: Management Statements - In a December statement, management indicated no awareness of any material undisclosed corporate developments that could explain the stock's fluctuations [2] - The founder and Global Group CEO, How Kok Choong, emphasized the company's focus on diversifying into health and wellness and sustainable green energy to enhance sustainable equity performance value [2]

Core Viewpoint - Agape ATP Corporation's stock experienced significant volatility, with a notable after-hours surge of 43.89% to $0.13, despite a prior closing price of $0.090, which represented a decline of 25.86% [1][2]. Company Statement - The company addressed the recent stock volatility, stating that management is unaware of any undisclosed corporate developments or adverse operating conditions that could explain the price fluctuations [2]. - Agape ATP confirmed that its operations are continuing as usual [2]. Management Commentary - Prof Dato' Sri Dr How Kok Choong, the founder and Global Group CEO, emphasized the company's commitment to diversifying its businesses in health and wellness, as well as sustainable green energy, to enhance sustainable equity performance for investors [3]. - The company pledged to maintain timely disclosures of developments through regulatory filings [3]. Recent Financial Performance - For the third quarter, Agape ATP reported revenue of $370,590, a decrease from $465,500 in the second quarter, with a loss of $0.01 per share, consistent with the previous quarter [4]. Trading Metrics - Year-to-date, ATPC shares have declined by 92.24%, with a market capitalization of $4.55 million. The stock has traded within a 52-week range of $0.05 to $2.93 [5]. - Benzinga's Edge Stock Rankings indicate a negative price trend for ATPC across all time frames [5].

Core Viewpoint - Agape ATP Corporation (ATPC) addresses recent stock price volatility, confirming stable business operations and no known adverse conditions affecting performance [1][2]. Company Operations - The company continues to operate normally and is not aware of any undisclosed corporate developments that could explain stock price fluctuations [1]. - ATPC is committed to transparency and will communicate material developments through timely disclosures and regulatory filings [2]. Business Focus - ATPC is focused on diversifying its business in health and wellness products and sustainable green energy to enhance sustainable equity performance for investors [2]. - The company specializes in health and wellness products and energy-saving solutions, aiming to improve quality of life and promote sustainable development [3].

Core Insights - After-hours trading in the U.S. saw significant gains in small-cap and micro-cap biotech stocks, driven by a mix of catalyst-driven moves and sentiment-based rebounds following the Fed's rate cut Group 1: Notable After-Hours Gainers - Agape ATP Corp. (ATPC) surged 29.41% after hours to $0.088, despite no specific news, reflecting a broader risk-on sentiment in micro-cap stocks [1] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) rose 12.76% after hours to $11.57, driven by anticipation of a key clinical update on its Phase 1a study of CRB-913 [2] - Anebulo Pharmaceuticals, Inc. (ANEB) increased 8.37% after hours to $2.33, aligning with the overall positive sentiment in small-cap biotech [3] - Cue Biopharma, Inc. (CUE) gained 13.12% after hours to $0.54, with no new developments, indicating a macro-driven recovery in biotech [4] - Curis, Inc. (CRIS) saw a 7.68% increase after hours to $1.3999, following positive clinical data presented at the ASH Annual Meeting [5] - Skye Bioscience, Inc. (SKYE) rose 7.02% after hours to $1.22, benefiting from the overall biotech market lift [6] - Cerus Corporation (CERS) increased 3.17% after hours to $1.95, continuing its upward trend after announcing a purchasing agreement with Blood Centers of America [7]

Core Insights - The market has experienced significant price movements among several companies, with notable declines in stock values, indicating a critical reassessment of their market positions [1][7] Company Summaries - WORK Medical Technology Group Ltd. (NASDAQ:WOK) saw a dramatic stock price decrease of 96.00% to $0.22, despite its subsidiary securing a $114,000 service contract, with trading volume reaching 75,256,805 [2][8] - Agape ATP Corporation (NASDAQ:ATPC) experienced a 95.09% drop in stock price to $0.06, even with a strategic partnership involving a purchase order for EN590 diesel and Jet Fuel A1, and a trading volume of 81,386,239 [3][8] - POMDOCTOR Ltd. (NASDAQ:POM) reported an 89.11% decline in stock price to $0.59, following the release of its unaudited financial results for the first half of fiscal 2025, indicating challenges in balancing expansion and operational discipline [4][8] - ChowChow Cloud International Ho (NYSE American:CHOW) saw an 87.69% decrease in stock price to $1.44 after closing its IPO, raising nearly $12 million, with a significant drop from a year-high of $21.91 [5] - Aimei Health Technology Co., Ltd (Symbol: AFJK) experienced a 62.15% decrease in stock price to $33.5, following a dramatic surge and subsequent decline in after-hours trading, reflecting notable market adjustments [6]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Chijet Motor Company, Inc. (CJET) is up 40% at $2.67 - JX Luxventure Group Inc. (JXG) is up 19% at $4.12 - Inspire Medical Systems, Inc. (INSP) is up 15% at $103.50 - Epsium Enterprise Limited (EPSM) is up 15% at $4.14 - Oscar Health, Inc. (OSCR) is up 12% at $15.13 - Green Dot Corporation (GDOT) is up 11% at $13.21 - Butterfly Network, Inc. (BFLY) is up 6% at $2.82 - Cullinan Therapeutics, Inc. (CGEM) is up 5% at $10.00 - Vir Biotechnology, Inc. (VIR) is up 5% at $5.99 - Nvni Group Limited (NVNI) is up 5% at $3.17 [3] Premarket Losers - Clearside Biomedical, Inc. (CLSD) is down 69% at $0.82 - Twin Hospitality Group Inc. (TWNP) is down 20% at $2.84 - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is down 15% at $1.35 - Mobile-Network Solutions (MNDR) is down 12% at $4.16 - Waldencast plc (WALD) is down 10% at $2.75 - authID Inc. (AUID) is down 9% at $1.21 - EZGO Technologies Ltd. (EZGO) is down 6% at $1.98 - SciSparc Ltd. (SPRC) is down 5% at $2.34 - Twin Vee Powercats Co. (VEEE) is down 5% at $1.70 - Agape ATP Corporation (ATPC) is down 5% at $1.22 [4]

Revenue Performance - Revenue for Q3 2025 was $370,593, an increase of $39,304 or approximately 11.9% compared to $331,289 in Q3 2024[240][241] - Revenue from the network marketing business decreased by $11,947, or approximately 41.0%, while revenue from skin care and healthcare products increased by $72,160 or approximately 392.1%[241][242] - For the nine months ended September 30, 2025, total revenue was $1,125,129, an increase of $162,158 or approximately 16.8% compared to $962,971 in the same period of 2024[255][256] - Revenue from skin care and healthcare products for the nine months ended September 30, 2025 increased by $136,285 or approximately 740.5%[256] Profitability and Loss - Gross profit for Q3 2025 was $239,103, representing a gross margin of approximately 64.5%, up from $184,185 and a gross margin of 55.6% in Q3 2024[246] - Net loss for Q3 2025 increased to $595,370 from a net loss of $524,039 in Q3 2024, an increase of $71,331[254] - Net loss increased from $1,659,449 for the nine months ended September 30, 2024, to $1,931,535 for the same period in 2025, an increase of $272,086[268] Operating Expenses - Total operating expenses for Q3 2025 were $840,424, an increase of $108,129 or approximately 14.8% from $732,295 in Q3 2024[247] - Cost of revenue for the nine months ended September 30, 2025 was $520,800, an increase of $138,995 or approximately 36.4% from $381,805 in 2024[258] - General and administrative expenses for the nine months ended September 30, 2025 amounted to $2,324,451, an increase of $171,562 or approximately 8.0% from $2,152,889 in 2024[264] - Commission expenses for the nine months ended September 30, 2025 increased by $27,777 or approximately 117.8% to $51,350 compared to $23,573 in 2024[263] Cash Flow and Working Capital - Net cash used in operating activities for the nine months ended September 30, 2025, was $2,205,074, compared to $2,080,879 for the same period in 2024[270] - Net cash used in investing activities for the nine months ended September 30, 2025, was $23,000,667, primarily from advances for investment[273] - Net cash provided by financing activities for the nine months ended September 30, 2025, was $23,297,009, consisting of proceeds from the issuance of common stock for $23,000,000[274] - Working capital as of September 30, 2025, was $22,585,047, compared to $1,656,571 as of December 31, 2024[269] Accounting Standards and Regulations - The FASB issued ASU 2023-09 requiring companies to disclose specific categories in the rate reconciliation if the effect is equal to or greater than 5% of the amount computed by multiplying pretax income by the applicable statutory income tax rate, effective after December 15, 2024[303] - The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statements[303] - The FASB issued ASU 2024-01 clarifying the scope application of profits interest and similar awards, effective for annual reporting periods beginning after December 15, 2024[300] - The adoption of ASU 2024-01 has no material impact on the Company's consolidated financial statements[300] - The FASB issued ASU 2024-02 to remove extraneous references in accounting guidance, effective for annual reporting periods beginning after December 15, 2024, with no significant impact expected[301] - The Company has reviewed all recently issued accounting standards updates and is evaluating their applicability and impact[302] - The FASB issued ASU 2024-03 requiring additional disclosures about the nature of expenses in the income statement, effective after December 15, 2026[304] - The Company is currently evaluating the effect of adopting ASU 2024-03[304] Credit Risk and Allowance - The Company believes that its concentration of credit risk in trade receivables is mitigated by an ongoing credit evaluation process and short collection terms[311] - The Company does not generally require collateral from customers and evaluates the need for an allowance for credit loss based on specific customer credit risk factors[311] - The allowance for credit loss was recognized at $6,559 as of September 30, 2025, down from $32,857 as of December 31, 2024[284] Assets and Liabilities - The carrying amounts of operating right-of-use assets and property, plant, and equipment were $119,021 and $15,122, respectively, as of September 30, 2025[281] - Accumulated deficits increased to $11,420,899 as of September 30, 2025, from $9,518,045 as of December 31, 2024[269] - The company has no significant off-balance sheet arrangements that could materially affect its financial condition as of September 30, 2025[277]

Financial Performance - For the three months ended June 30, 2025, the company generated revenue of $465,499, an increase of $152,460 or approximately 48.7% compared to $313,039 for the same period in 2024[231] - Revenue from the company's network marketing business decreased by $13,097, or approximately 44.8%, while new revenue streams included $55,446 from wellness and wellbeing lifestyle and $135,434 from green energy[231] - For the six months ended June 30, 2025, total revenue was $754,536, an increase of $122,854 or approximately 19.4% compared to $631,682 in 2024[246] Cost and Expenses - Cost of revenue for the three months ended June 30, 2025 amounted to $256,559, an increase of $137,081 or approximately 114.7% from $119,478 in 2024[233] - Total operating expenses for the three months ended June 30, 2025 were $845,901, an increase of $198,755 or approximately 30.7% from $647,146 in 2024[237] - Cost of revenue for the six months ended June 30, 2025 was $389,310, an increase of $154,609 or approximately 65.9% from $234,701 in 2024[248] Profitability - Gross profit for the three months ended June 30, 2025 was $208,940, with a gross margin of approximately 44.9%, down from $193,561 and 61.8% in 2024[236] - Gross profit for the six months ended June 30, 2025 was $365,226, with a gross margin of approximately 48.4%, down from $396,981 and 62.8% in 2024[250] - The company recorded a net loss of $623,246 for the three months ended June 30, 2025, an increase of $190,931 from a net loss of $432,315 in 2024[245] - Net loss increased to $1,336,165 for the six months ended June 30, 2025, compared to a net loss of $1,135,410 for the same period in 2024, representing an increase of $200,755[258] Cash Flow - Net cash used in operating activities for the six months ended June 30, 2025, was $1,948,332, compared to $1,656,000 for the same period in 2024, indicating a higher cash outflow[260] - Net cash used in investing activities surged to $23,000,660 for the six months ended June 30, 2025, compared to only $3,567 in 2024, primarily due to advances for investment[263] - Net cash provided by financing activities was $23,115,678 for the six months ended June 30, 2025, mainly from the issuance of common stock for $23,000,000[265] Financial Position - Working capital as of June 30, 2025, was $23,149,202, a significant increase from $1,656,571 as of December 31, 2024[259] - The company had accumulated deficits of $10,834,072 as of June 30, 2025, compared to $9,518,045 as of December 31, 2024[259] - The allowance for credit loss increased to $42,838 as of June 30, 2025, from $32,857 as of December 31, 2024[276] Tax and Accounting Standards - The provision for income taxes was $0 for the six months ended June 30, 2025, compared to $16,678 for the same period in 2024[257] - The FASB issued ASU 2023-09 requiring companies to disclose specific categories in the rate reconciliation if the effect of reconciling items is equal to or greater than 5% of the amount computed by multiplying pretax income by the applicable statutory income tax rate[296] - The adoption of ASU 2023-07 is effective for annual reporting periods beginning after December 15, 2023, with no material impact on the consolidated financial statements[291] - The Company is currently evaluating the impact of ASU 2024-01 on its consolidated financial statements, which clarifies the scope application of profits interest and similar awards[292] - The amendments in ASU 2024-02 are effective for annual reporting periods beginning after December 15, 2024, and are not expected to result in significant accounting changes[293] - The FASB issued ASU 2024-03 requiring additional disclosures about the nature of expenses included in the income statement, effective for annual periods beginning after December 15, 2026[297] - The Company is evaluating the effect of adopting ASU 2024-04 regarding the accounting for induced conversions of convertible debt instruments, effective after December 15, 2025[298] - The Company has reviewed all recently issued accounting standards updates and considers their applicability and impact[295] - There are no new accounting standards that will have a material impact on the consolidated financial position or cash flows, except for those mentioned[294] Risk Management - The Company believes that its concentration of credit risk in trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms[303] - The Company does not currently hedge exposures denominated in foreign currencies, limiting its direct foreign exchange risk[302] - The company recorded no inventory write-downs for the six months ended June 30, 2025, but had an inventory write-off of $6,897[271] - The company had no significant off-balance sheet arrangements as of June 30, 2025, that could materially affect its financial condition[268]

Revenue Performance - For the three months ended March 31, 2025, the company generated revenue of $289,037, a decrease of approximately 9.3% compared to $318,643 for the same period in 2024[234]. - Revenue from the company's network marketing business decreased by $10,532 or approximately 28.4%, while revenue from complementary health therapies decreased by $29,318 or approximately 10.4%[234]. Cost and Profitability - Cost of revenue increased by $17,528 or approximately 15.2%, amounting to $132,751 for the three months ended March 31, 2025[236]. - Gross profit for the three months ended March 31, 2025 was $156,286, representing a gross margin of 54.1%, down from 63.8% in the same period of 2024[239]. - Selling expenses increased by $12,704 or approximately 25.2%, totaling $63,052 for the three months ended March 31, 2025[241]. - Net loss increased by $9,825, resulting in a net loss of $712,919 for the three months ended March 31, 2025, compared to a net loss of $703,094 for the same period in 2024[247]. Cash Flow and Working Capital - As of March 31, 2025, the company had working capital of $23,775,576, significantly up from $1,656,571 as of December 31, 2024[248]. - Net cash used in operating activities for the three months ended March 31, 2025 was $1,453,874, compared to $1,243,460 for the same period in 2024[249]. - Net cash used in investing activities for the three months ended March 31, 2025 was $23,000,649, primarily from advances for investment[252]. - Net cash provided by financing activities for the three months ended March 31, 2025 was $22,994,658, compared to a net cash used of $899 in the same period of 2024[255]. Asset Management - As of March 31, 2025, the allowance for credit loss was recognized at $41,360, an increase from $32,857 as of December 31, 2024, reflecting a growth of approximately 25.3%[264]. - The carrying amounts of operating right-of-use assets were $189,059 as of March 31, 2025, down from $224,595 as of December 31, 2024, indicating a decrease of about 15.8%[261]. - The Company recorded inventory write-offs of $6,777 for the three months ended March 31, 2025, compared to $0 for the same period in 2024[259]. - The Company has not recognized any impairment losses on operating right-of-use assets and property, plant, and equipment as of March 31, 2025[261]. Revenue Recognition and Accounting Policies - The Company’s revenue recognition follows the five-step model under ASC Topic 606, ensuring that revenue reflects the transfer of goods and services to customers[268]. - The Company’s sales of skin care, health, and wellness products are recognized when control is transferred to the customer, with a return period of 60 days[271]. - The Company evaluates the need for an allowance for credit loss based on ongoing credit evaluations and current economic conditions[291]. - The Company has not hedged exposures denominated in foreign currencies, limiting direct foreign exchange risk[290]. - The adoption of ASU 2023-07 regarding segment reporting is expected to have no material impact on the consolidated financial statements[280]. Equity and Financing - The Company issued Representative's Warrants to purchase up to 115,500 shares at $4.4 per share, effective from October 13, 2023[266].

Revenue Performance - Total revenue for the year ended December 31, 2024 decreased by $108,341, or approximately 7.6%, compared to 2023, with network marketing revenue dropping by $259,072, or approximately 65.4%[158] - Revenue from the provision of complementary health therapies increased by $87,622, or approximately 8.5%, during the same period[159] - The company launched new revenue streams in wellness and wellbeing lifestyle and green energy, contributing $64,854 in revenue[159] Cost and Expenses - Cost of revenue for 2024 amounted to $563,599, representing approximately 42.6% of revenue, an increase of $69,083, or approximately 14.0% from 2023[161] - Gross profit for 2024 was $759,148, with a gross margin of approximately 57.4%, down from $936,572 and 65.4% in 2023[163] - Selling expenses for 2024 significantly decreased by $466,291, or approximately 74.1%, totaling $162,712 compared to $629,003 in 2023[166] - General and administrative expenses increased by $768,858, or approximately 32.4%, totaling $3,134,874 in 2024 due to higher executive salaries and Nasdaq listing fees[168] Net Loss and Cash Flow - Net loss for the year ended December 31, 2024 was $2,486,044, an increase of $376,109, or approximately 17.8%, compared to the previous year[171] - Working capital as of December 31, 2024 was $1,656,571, a decrease from $4,113,614 in 2023[172] - Net cash used in operating activities for 2024 was $2,726,215, compared to $2,001,823 in 2023[173] - Net cash used in financing activities for the year ended December 31, 2024 was $11,856, primarily for the reduction of finance lease liability[177] - Net cash provided by financing activities for the year ended December 31, 2023 was $5,398,037, consisting of proceeds from issuance of common stock of $5,501,520, cash used for shares repurchased of $93,889, and reduction of finance lease liability of $9,594[177] Inventory and Credit Management - The company recognized an inventory write-down of $7,081 for the year ended December 31, 2024, compared to $0 for 2023[181] - The allowance for expected credit loss increased to $32,857 for the year ended December 31, 2024, from $542 in 2023[185] - Credit risk is primarily associated with accounts receivable, which the company mitigates through ongoing credit evaluations and short collection terms[214] - The company does not generally require collateral from customers, relying instead on credit evaluations[214] - The need for an allowance for doubtful accounts is evaluated based on specific customer credit risk, historical trends, and other relevant information[214] Accounting and Financial Reporting - The company adopted ASU 2014-09 for revenue recognition, which requires identifying performance obligations and recognizing revenue when control of goods and services transfers to customers[188] - The company derives revenues from sales contracts recognized when control of skin care, health, and wellness products is transferred to customers[191] - The company provides products and services for sustainability and energy savings, recognizing revenue based on the percentage of cost incurred[198] - The adoption of recent accounting standards has no material impact on the consolidated financial statements for the year ended December 31, 2024[211] Foreign Currency and Risk Management - The majority of the company's revenues are denominated in Malaysian Ringgit, while expenses are in Malaysian Ringgit, U.S. Dollar, and Hong Kong Dollar[212] - The company does not currently hedge exposures denominated in foreign currencies or use derivative financial instruments[212] - The value of the company's Common Stock may be affected by the foreign exchange rates between U.S. Dollar and Malaysian Ringgit, and U.S. Dollar and Hong Kong Dollar[213]